Home ETF List About

Portfolio Holdings Detail for ISIN IE00B6SPMN59
Stock Name / FundiShares Edge S&P 500 Minimum Volatility UCITS ETF USD (Acc)
IssuerBlackrock
Entity holding fund iShares VI Public Limited Company
Entity TypeUmbrella investment company with variable capital and having segregated liability between its funds
Entity LEI 549300VML6THE3JJOS76
ETF TickerSPMV(USD) LSE
ETF TickerIBCK(EUR) F
ETF TickerMVUS.MI(EUR) CXE
ETF TickerSPLVz(CHF) CXE
ETF TickerSPMV.LS(USD) CXE
ETF TickerMVUS(EUR) ETF Plus
ETF TickerSPMV(EUR) ETF Plus
ETF TickerSPMV.L(GBP) LSE

Holdings detail for REGN

Stock NameRegeneron Pharmaceuticals Inc
TickerREGN(USD) NASDAQ
TYPECommon Stock
CountryUSA
ISINUS75886F1075
LEI549300RCBFWIRX3HYQ56

Show aggregate REGN holdings

News associated with REGN

Regeneron And Sanofi : CHMP Recommends EU Approval Of Dupixent For Chronic Spontaneous Urticaria
(RTTNews) - Regeneron Pharmaceuticals Inc. (REGN) and Sanofi announced that the European Medicines Agency's Committee for Medicinal Products for Human Use or CHMP has adopted a positive opinion recommending the approval of Dupixent (dupilumab) in the European Union for treating c - 2025-09-22 02:12:20
Peek Under The Hood: JEPQ Has 10% Upside
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-09-08 08:26:56
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Given Consensus Rating of “Moderate Buy” by Brokerages
Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) have been given an average recommendation of “Moderate Buy” by the twenty-six analysts that are currently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell rating, six have issued a hold rating, sixteen have assigned a buy rating and three […] - 2025-08-26 02:16:48
LABU, INCY, UTHR, REGN: ETF Outflow Alert
Looking today at week-over-week shares outstanding changes among the universe of ETFs covered at ETF Channel, one standout is the Direxion Daily S&P Biotech Bull 3x Shares (Symbol: LABU) where we have detected an approximate $67.3 million dollar outflow -- that's a 9.4% dec - 2025-08-20 12:04:03
Regeneron Pharmaceuticals (NASDAQ:REGN) versus Cadrenal Therapeutics (NASDAQ:CVKD) Head-To-Head Analysis
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) and Cadrenal Therapeutics (NASDAQ:CVKD – Get Free Report) are both medical companies, but which is the better investment? We will contrast the two companies based on the strength of their dividends, risk, analyst recommendations, valuation, institutional ownership, profitability and earnings. Volatility and Risk Regeneron Pharmaceuticals has a beta […] - 2025-08-20 02:22:48
Truist Financial Cuts Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target to $812.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target reduced by Truist Financial from $940.00 to $812.00 in a research note published on Monday,Benzinga reports. They currently have a buy rating on the biopharmaceutical company’s stock. REGN has been the topic of several other reports. The Goldman Sachs Group dropped their price target on […] - 2025-08-14 03:00:52
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Position Raised by Blair William & Co. IL
Blair William & Co. IL lifted its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.2% in the 1st quarter, Holdings Channel reports. The fund owned 1,282 shares of the biopharmaceutical company’s stock after buying an additional 27 shares during the period. Blair William & Co. IL’s holdings in Regeneron Pharmaceuticals were worth […] - 2025-08-11 06:26:50
Harbour Investments Inc. Sells 32 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Harbour Investments Inc. reduced its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 7.4% in the first quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 403 shares of the biopharmaceutical company’s stock after selling 32 shares during the quarter. Harbour Investments Inc.’s holdings in […] - 2025-08-07 09:40:47
We Did The Math SPYX Can Go To $58
Looking at the underlying holdings of the ETFs in our coverage universe at ETF Channel, we have compared the trading price of each holding against the average analyst 12-month forward target price, and computed the weighted average implied analyst target price for the ETF itself. - 2025-08-07 08:58:54
409 Shares in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Purchased by Arkadios Wealth Advisors
Arkadios Wealth Advisors purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The fund purchased 409 shares of the biopharmaceutical company’s stock, valued at approximately $259,000. Several other institutional investors and hedge funds also […] - 2025-08-07 05:38:53
Regeneron Pharmaceuticals (NASDAQ:REGN) Stock Price Expected to Rise, BMO Capital Markets Analyst Says
Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) had its price target upped by stock analysts at BMO Capital Markets from $600.00 to $640.00 in a research report issued on Monday,Benzinga reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. BMO Capital Markets’ price target indicates a potential upside of 12.30% from […] - 2025-08-06 03:12:48
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Receives $828.86 Consensus Target Price from Brokerages
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has been given a consensus rating of “Moderate Buy” by the twenty-four ratings firms that are currently covering the firm, Marketbeat.com reports. One investment analyst has rated the stock with a sell recommendation, six have issued a hold recommendation, fifteen have assigned a buy recommendation and two […] - 2025-08-04 02:59:01
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 19:31:54
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:40:40
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:35:36
Stocks Slump on Tariffs and Weak US Job Growth
The S&P 500 Index ($SPX ) (SPY ) today is down -1.70%, the Dow Jones Industrials Index ($DOWI ) (DIA ) is down -1.48%, and the Nasdaq 100 Index ($IUXX ) (QQQ ) is down -2.01%. September E-mini S&P futures (ESU25 ) are down -1.75%, and September E-mini Nasdaq futures... - 2025-08-01 14:02:25
Nasdaq 100 Movers: MRVL, REGN
In early trading on Friday, shares of Regeneron Pharmaceuticals, topped the list of the day's best performing components of the Nasdaq 100 index, trading up 3.6%. Year to date, Regeneron Pharmaceuticals, has lost about 20.7% of its value. And the worst performing Nasdaq 100 co - 2025-08-01 11:30:09
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Choreo LLC
Choreo LLC boosted its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 0.9% during the first quarter, according to its most recent Form 13F filing with the SEC. The fund owned 3,746 shares of the biopharmaceutical company’s stock after acquiring an additional 32 shares during the period. Choreo LLC’s holdings in Regeneron Pharmaceuticals […] - 2025-07-24 07:22:56
Crestwood Advisors Group LLC Grows Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Crestwood Advisors Group LLC increased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.7% in the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 467 shares of the biopharmaceutical company’s stock after purchasing an additional 25 shares during the quarter. Crestwood Advisors Group […] - 2025-07-24 05:47:12
Kestra Private Wealth Services LLC Has $1.31 Million Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Kestra Private Wealth Services LLC grew its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 6.9% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 2,058 shares of the biopharmaceutical company’s stock after buying an additional 132 shares during the quarter. […] - 2025-07-23 07:50:58
Larson Financial Group LLC Has $34,000 Stock Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Larson Financial Group LLC lessened its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 34.6% during the 1st quarter, according to its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 53 shares of the biopharmaceutical company’s stock after selling 28 shares during the quarter. Larson […] - 2025-07-23 06:30:53
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Shares Purchased by Alps Advisors Inc.
Alps Advisors Inc. raised its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 71.0% during the 1st quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 530 shares of the biopharmaceutical company’s stock after purchasing an additional 220 shares during the quarter. Alps Advisors Inc.’s […] - 2025-07-17 05:50:54
Stratos Wealth Partners LTD. Sells 115 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Stratos Wealth Partners LTD. trimmed its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 18.5% in the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor owned 506 shares of the biopharmaceutical company’s stock after selling 115 shares during the period. Stratos Wealth Partners […] - 2025-07-16 04:58:54
Allworth Financial LP Reduces Position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Allworth Financial LP trimmed its stake in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 14.3% in the 1st quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 821 shares of the biopharmaceutical company’s stock after selling 137 shares during the period. Allworth Financial […] - 2025-07-15 08:20:00
Regeneron Pharmaceuticals (NASDAQ:REGN) Price Target Raised to $584.00
Regeneron Pharmaceuticals (NASDAQ:REGN – Free Report) had its price target increased by UBS Group from $560.00 to $584.00 in a report issued on Friday,Benzinga reports. The brokerage currently has a neutral rating on the biopharmaceutical company’s stock. Several other research analysts also recently commented on REGN. BMO Capital Markets reduced their price objective on Regeneron […] - 2025-07-14 03:30:48
Brown Advisory Inc. Reduces Holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Brown Advisory Inc. lowered its stake in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 5.5% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 4,269 shares of the biopharmaceutical company’s stock after selling 247 shares during the quarter. Brown Advisory Inc.’s […] - 2025-07-13 05:54:54
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) Stock Holdings Cut by D.A. Davidson & CO.
D.A. Davidson & CO. reduced its position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 2.8% in the first quarter, according to the company in its most recent 13F filing with the SEC. The institutional investor owned 732 shares of the biopharmaceutical company’s stock after selling 21 shares during the quarter. D.A. […] - 2025-07-11 05:32:52
Brokerages Set Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) PT at $813.57
Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Get Free Report) has received an average recommendation of “Moderate Buy” from the twenty-five ratings firms that are covering the stock, MarketBeat reports. One research analyst has rated the stock with a sell rating, six have issued a hold rating, fifteen have assigned a buy rating and three have issued […] - 2025-07-10 03:07:00
DAVENPORT & Co LLC Makes New Investment in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
DAVENPORT & Co LLC purchased a new position in shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) during the first quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The institutional investor purchased 427 shares of the biopharmaceutical company’s stock, valued at approximately $271,000. A number of other institutional […] - 2025-07-09 05:11:22
Bessemer Group Inc. Sells 3,860 Shares of Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN)
Bessemer Group Inc. decreased its position in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 76.0% in the 1st quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,218 shares of the biopharmaceutical company’s stock after selling 3,860 shares during the period. Bessemer Group […] - 2025-07-01 05:46:52

iShares Edge S&P 500 Minimum Volatility UCITS ETF USD (Acc) REGN holdings

DateNumber of REGN Shares HeldBase Market Value of REGN SharesLocal Market Value of REGN SharesChange in REGN Shares HeldChange in REGN Base ValueCurrent Price per REGN Share HeldPrevious Price per REGN Share Held
2025-09-18 (Thursday)17,610USD 10,543,283REGN holding increased by 232628USD 10,543,2830USD 232,628 USD 598.71 USD 585.5
2025-09-17 (Wednesday)17,610USD 10,310,655REGN holding increased by 183848USD 10,310,6550USD 183,848 USD 585.5 USD 575.06
2025-09-16 (Tuesday)17,610REGN holding decreased by -156USD 10,126,807REGN holding decreased by -45827USD 10,126,807-156USD -45,827 USD 575.06 USD 572.59
2025-09-15 (Monday)17,766REGN holding increased by 156USD 10,172,634REGN holding increased by 311034USD 10,172,634156USD 311,034 USD 572.59 USD 560
2025-09-12 (Friday)17,610REGN holding decreased by -78USD 9,861,600REGN holding decreased by -188722USD 9,861,600-78USD -188,722 USD 560 USD 568.2
2025-09-11 (Thursday)17,688USD 10,050,322REGN holding increased by 218801USD 10,050,3220USD 218,801 USD 568.2 USD 555.83
2025-09-10 (Wednesday)17,688USD 9,831,521REGN holding decreased by -12382USD 9,831,5210USD -12,382 USD 555.83 USD 556.53
2025-09-09 (Tuesday)17,688REGN holding decreased by -56USD 9,843,903REGN holding decreased by -65056USD 9,843,903-56USD -65,056 USD 556.53 USD 558.44
2025-09-08 (Monday)17,744USD 9,908,959USD 9,908,959
Share price and value of shares held is calculated on the adjusted close price of each day (row). Changes between days reflect the gain/loss of the portfolio as a result of changes in the adjusted close price and changes in the holdings

Share Trades of REGN by Blackrock for IE00B6SPMN59

Show aggregate share trades of REGN

DateActionQuantityMarket HighMarket LowLikely Trade PriceLikely Trade Value (Profit/Loss)Average Price previous trades
2025-09-16SELL-156 575.060* 646.95 Profit of 100,925 on sale
2025-09-15BUY156 572.590* 647.41
2025-09-12SELL-78 560.000* 647.96 Profit of 50,541 on sale
2025-09-09SELL-56 556.530* 649.64 Profit of 36,380 on sale
2025-07-30SELL-189 554.580* 650.92 Profit of 123,024 on sale
2025-07-29BUY728 558.145* 651.53
2025-07-16SELL-390 547.930* 652.87 Profit of 254,621 on sale
2025-07-14SELL-52 570.590* 654.12 Profit of 34,014 on sale
2025-07-11SELL-78 567.740* 654.70 Profit of 51,067 on sale
2025-07-10SELL-26 559.760* 655.34 Profit of 17,039 on sale
2025-07-09SELL-52 552.580* 656.04 Profit of 34,114 on sale
2025-07-07BUY25 538.110* 657.60
2025-07-03SELL-390 547.360* 659.15 Profit of 257,067 on sale
2025-07-02SELL-50 547.740* 659.93 Profit of 32,996 on sale
2025-06-23SELL-52 511.920* 664.02 Profit of 34,529 on sale
2025-06-20SELL-26 509.720* 665.14 Profit of 17,294 on sale
2025-06-18SELL-50 513.580* 667.39 Profit of 33,370 on sale
2025-06-16SELL-312 522.680* 669.67 Profit of 208,937 on sale
2025-06-13SELL-1,278 529.240* 670.73 Profit of 857,198 on sale
2025-06-12SELL-1,151 521.840* 671.87 Profit of 773,323 on sale
2025-06-11SELL-52 518.600* 673.05 Profit of 34,999 on sale
2025-06-06BUY78 493.220* 676.87
2025-06-05BUY104 483.070* 678.41
2025-05-28SELL-78 591.850* 686.07 Profit of 53,513 on sale
2025-05-27BUY78 603.260* 686.76
2025-05-23SELL-234 588.340* 688.44 Profit of 161,096 on sale
2025-05-22BUY52 596.850* 689.23
2025-05-20BUY234 614.790* 690.63
2025-05-16BUY99 594.320* 692.33
2025-05-15BUY100 584.990* 693.30
2025-05-14SELL-675 571.360* 694.40 Profit of 468,723 on sale
2025-05-13BUY50 574.160* 695.51
2025-05-12BUY125 575.630* 696.62
2025-05-09SELL-100 527.780* 698.20 Profit of 69,820 on sale
2025-05-08BUY75 547.670* 699.62
2025-05-07SELL-125 560.930* 700.94 Profit of 87,617 on sale
2025-04-30SELL-25 598.760* 706.42 Profit of 17,660 on sale
2025-04-28SELL-150 610.860* 708.80 Profit of 106,320 on sale
2025-04-23BUY25 587.850* 712.34
2025-04-15BUY325 557.910* 722.37
2025-04-14BUY50 571.060* 724.09
2025-04-09SELL-150 576.720* 729.92 Profit of 109,488 on sale
2025-04-08BUY75 556.810* 731.98
2025-04-04BUY150 573.450* 735.85
2025-04-02BUY73 625.600* 737.21
2025-04-01SELL-225 617.000* 738.72 Profit of 166,211 on sale
2025-03-31BUY1,184 634.230* 740.04
2025-03-28BUY150 637.360* 741.36
2025-03-27BUY294 635.830* 742.73
2025-03-26BUY748 640.140* 744.08
2025-03-25BUY513 634.140* 745.54
2025-03-24SELL-75 661.000* 746.68 Profit of 56,001 on sale
2025-03-21SELL-4,100 658.480* 747.89 Profit of 3,066,362 on sale
2025-03-19BUY91 672.360* 750.16
2025-03-17SELL-188 678.420* 752.43 Profit of 141,457 on sale
2025-03-14SELL-94 666.870* 753.69 Profit of 70,847 on sale
2025-03-13SELL-94 680.610* 754.78 Profit of 70,949 on sale
2025-03-12SELL-188 689.500* 755.77 Profit of 142,085 on sale
2025-03-07BUY282 707.510* 757.31
2025-02-28BUY282 698.740* 762.10
2025-02-26BUY376 706.940* 764.11
2025-02-21BUY564 700.330* 766.99
2025-02-18BUY188 680.000* 771.68
2025-02-11BUY470 665.460* 782.71
2025-02-07BUY188 710.000* 786.47
2025-02-06BUY94 722.070* 787.96
2025-02-05BUY282 716.720* 789.66
2025-02-04BUY94 697.050* 791.92
2025-01-31SELL-188 672.980* 798.18 Profit of 150,057 on sale
2025-01-29SELL-188 687.270* 804.28 Profit of 151,205 on sale
2024-12-10SELL-94 778.500* 819.95 Profit of 77,076 on sale
2024-12-09SELL-94 788.000* 820.98 Profit of 77,173 on sale
2024-11-27SELL-188 754.870* 842.54 Profit of 158,398 on sale
2024-11-21SELL-376 744.500* 862.81 Profit of 324,418 on sale
2024-11-20SELL-188 743.350* 869.45 Profit of 163,457 on sale
2024-11-18SELL-188 762.000* 883.97 Profit of 166,186 on sale
2024-11-12SELL-564 821.000* 888.17 Profit of 500,926 on sale
2024-11-08SELL-1,504 828.420* 892.43 Profit of 1,342,221 on sale
2024-11-07SELL-658 824.480* 897.66 Profit of 590,661 on sale
Market high and low price is on the date.

* (if shown) = market close price used not a projected price. This is used when we do not have market data available to calculate a projection

The likely trade price/value is our estimate on the likely price the trade took place at and is not the actual trade price. The likely LOSS/GAIN is our estimate. Where a profit/loss value is shown in the Likely Trade Value column, this is derived from matching trades between periods eg the most recent previous BUY is matched with the SELL for the same number of shares and the difference between the likely BUY price and likely SELL price is calculated. Where a profit or loss is shown in the Average Price of Previous Trades column, this is dervied using the likely trade price compared to the average of previous trades based on adjusted close

Shorting History of REGN

DateShorted VolumeShort Exempt VolumeTotal Shares Traded% Shorted
2025-09-19208,6591,635312,81266.7%
2025-09-18236,4853,679387,51961.0%
2025-09-17229,191716370,89561.8%
2025-09-16173,632584271,02064.1%
2025-09-15204,491251334,49661.1%
2025-09-12117,50433222,76052.7%
2025-09-11125,4783,137286,51643.8%
2025-09-10195,068481339,88557.4%
2025-09-09129,168994274,52047.1%
2025-09-08250,895396527,06247.6%
2025-09-05170,149290289,56658.8%
2025-09-04188,2272,103360,61952.2%
2025-09-03185,679344438,11142.4%
2025-09-02191,954138476,28840.3%
2025-08-29133,226685236,72656.3%
2025-08-28116,5602,177256,67545.4%
2025-08-27113,719465243,83646.6%
2025-08-26210,376450400,19952.6%
2025-08-25149,13068363,37741.0%
2025-08-22211,8223,244701,77030.2%
2025-08-21257,4923,416446,43957.7%
2025-08-20327,738572559,13358.6%
2025-08-19118,4722,191324,31136.5%
2025-08-18146,282388277,90952.6%
2025-08-15209,9233,375441,75247.5%
2025-08-14157,5693,623429,32736.7%
2025-08-13111,342233362,78630.7%
2025-08-12117,647171310,77537.9%
2025-08-11129,5132,676284,75745.5%
2025-08-08128,5591,038431,84129.8%
2025-08-07166,6481,560352,87747.2%
2025-08-06176,311624397,08944.4%
2025-08-05154,257115353,74443.6%
2025-08-04200,7581,913409,89749.0%
2025-08-01349,7753,745728,72048.0%
2025-07-31222,350476549,34440.5%
2025-07-30106,8391,689231,76146.1%
2025-07-29149,359276292,66751.0%
2025-07-28103,6871,380245,28742.3%
2025-07-25103,783556259,06940.1%
2025-07-24156,9742,397291,67753.8%
2025-07-23168,7341,708355,37247.5%
2025-07-22116,324617304,88038.2%
2025-07-2198,482900250,10739.4%
2025-07-18183,1741,051391,90946.7%

The data here is derived from FINRA daily shorted trade data. The Daily Short Sale Volume is the total volume of short trades that meet certain criteria on each trade date by 6 PM ET on the trade date. The detail trade data is derived from the monthly shorted trade data which will differ in aggregate. The detail trade data is derived from the transaction level data and includes ALL trades (including exempt) and the aggregation period extends beyond 6pm.

Back to Listing

Disclaimer

All information is provided as is without warranty and should be used for indicative purposes only. You should independently check data before making any investment decision. This information is derived from third party sources and we cannot guarantee that their data is current, accurate, complete, free from defects etc and we therefore accept no responsibility for how it may be used. We accept no liability for the reliability or accuracy of the data provided. We are not making recommendations for any financial instruments listed on this website.